Cullinan Therapeutics, Inc.
NASDAQ:CGEMMedical - Pharmaceuticals
+$0.62 today
- Market cap
- $584.94M
- Beta
- 0.01
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$3.73
Volume 1.06M
Average 0.99M
CGEM Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Cullinan Therapeutics, Inc.NASDAQ: CGEM
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow grows, but more slowly than its trailing trend
Q1 FY2026 free cash flow of $46.05M (cash outflow) rose 6.7% year over year, behind the +19.0% change in trailing-twelve-month free cash flow. Sequentially, it rose 20.8% from the prior quarter. Over 3 fiscal years it compounded at +11.2% a year.
Context
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +6.7% toward the trailing-twelve-month pace of +19.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (175.8M) USD
- Year-over-year change
- -21.0%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (175.8M) | -21.0% |
| FY2024 | 2024-12-31 | (145.3M) | -8.0% |
| FY2023 | 2023-12-31 | (134.48M) | -5.2% |
| FY2022 | 2022-12-31 | (127.8M) | -190.3% |
| FY2021 | 2021-12-31 | (44.02M) | — |
Free Cash Flow vs competitors
How CGEM compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +19.0% is the 5th highest of 10, against a peer median of +12.4%.
- Over three fiscal years its annual growth of +11.2% compares with a peer median of +7.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $369.81M USD | +253.2% | +15.3% | 52.7% | |
| LTM Sep 2026 | $320.88M USD | +70.1% | -9.1% | 23.6% | |
| LTM Jun 2026 | $208.29M USD | +47.9% | +94.1% | 198.4% | |
| LTM Mar 2026 | €188.49M EUR | +10.8% | — | 505.4% | |
| LTM Mar 2026 | $178.69M USD | +19.0% | +11.2% | — | |
| LTM Mar 2026 | $134.47M USD | +12.4% | +54.4% | — | |
| LTM Mar 2026 | $114.59M USD | -16.2% | +0.6% | 144.7% | |
| LTM Mar 2026 | $78.49M USD | +68.7% | +19.0% | 363.2% | |
| LTM Mar 2026 | $78.33M USD | -28.1% | -2.4% | — | |
| LTM Mar 2026 | $71.69M USD | -1.0% | -2.9% | 45.6% | |
| LTM Dec 2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding CGEM) | — | +12.4% | +7.9% | 98.7% | |
Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (67.49M) | 109.2M | (153.16M) | (167.58M) | (219.88M) |
| Depreciation & Amortization | 53K | 93K | 310K | 306K | 311K |
| Deferred Income Tax | 3.1M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 24.38M | 27.96M | 30.44M | 37.82M | 36.04M |
| Change in Working Capital | (3.54M) | 11.18M | (339K) | (389K) | 14.08M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (4.84M) | (509K) | (167K) | (812K) | (839K) |
| Other Working Capital | 1.29M | 11.69M | (172K) | 423K | 14.92M |
| Other Non-Cash Items | 67K | (275.09M) | (11.52M) | (15.47M) | (6.31M) |
| Operating Cash Flow | (43.43M) | (126.66M) | (134.28M) | (145.3M) | (175.75M) |
| Capital Expenditures | (589.23K) | (1.13M) | (208K) | 0 | (49K) |
| Acquisitions (Net) | 923K | 275M | (36.01K) | 0 | 0 |
| Purchases of Investments | (525.81M) | (377.92M) | (373.38M) | (721.13M) | (236.53M) |
| Sales of Investments | 192.04M | 352.93M | 409.4M | 584.82M | 416.57M |
| Other Investing Activities | (333.78K) | 91K | 36.01K | 0 | 0 |
| Investing Cash Flow | (333.78M) | 248.98M | 35.81M | (136.31M) | 179.99M |
| Debt Repayment | 0 | (2.2M) | 1.83M | 0 | 0 |
| Common Stock Issued | 267.27M | 8.4M | 38.39M | 262.65M | 1.09M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.52M | (32.13M) | 538K | 3.54M | 0 |
| Financing Cash Flow | 268.78M | (25.93M) | 40.75M | 266.19M | 1.09M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (108.42M) | 96.38M | (57.72M) | (15.43M) | 5.33M |
| Free Cash Flow | (44.02M) | (127.8M) | (134.48M) | (145.3M) | (175.8M) |
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
Intrinsic Alpha fair value
Locked
Current Price
$9.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.